FDA, including semaglutide in 2021 and tirzepatide in 2023
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
Bruxism and Jaw Discomfort Some patients report increased stress, sleep disturbances, or anxiety while adjusting to weight loss medications
Everyone will not lose the same amount of weight and results are a function of motivation, lifestyle, and consistent follow-up
According to the model, a population of 100,000 people on tirzepatide had over 46,000 fewer cases of obesity and 32,000 fewer cases of diabetes than a population treated with only a lifestyle management program